Sponsor
AB Science
Clinical research sponsor
Clinical trials
14 shownMasitinib in Patients With Mild Alzheimer's DiseaseNCT05564169 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGMasitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisNCT05441488 · lead sponsor · 2022-06-28
SUSPENDEDMasitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsNCT03771040 · lead sponsor · 2016-12-01
COMPLETEDMasitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT03761225 · lead sponsor · 2014-09-01
COMPLETEDMasitinib in Patients With Mild to Moderate Alzheimer's DiseaseNCT01872598 · lead sponsor · 2012-01-01
COMPLETEDEfficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisNCT01433497 · lead sponsor · 2011-08-01
COMPLETEDMasitinib in Refractory Active Rheumatoid ArthritisNCT01410695 · lead sponsor · 2011-07-01
TERMINATEDMasitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral CorticosteroidsNCT01449162 · lead sponsor · 2011-01-01
COMPLETEDMasitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid ArthritisNCT00913432 · lead sponsor · 2007-03-01
COMPLETEDActivity of Masitinib (AB1010) in Mild to Moderate Alzheimer's DiseaseNCT00976118 · lead sponsor · 2006-02-01
COMPLETEDEfficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent AsthmaNCT00842270 · lead sponsor · 2006-01-01
COMPLETEDMasitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisNCT01450488 · lead sponsor · 2005-06-01
COMPLETEDEfficacy of Oral AB1010 in Adult Patients With Active Rheumatoid ArthritisNCT00831922 · lead sponsor · 2004-09-01
COMPLETEDClinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.NCT06280755 · collaborator · 2024-03-01
RECRUITINGSponsor roles
lead sponsor13
collaborator1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.